In his weekly clinical update, Dr. Griffin informs us about “walking pneumonia”, the phase of the polio supplemental immunization campaign in Gaza, mpox circulation, the Marburg virus outbreak in Rwanda, the beginning of influenza season, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, contrasting public health concerns between the US and the UK, if mRNA boosters affect mucosal immunity against SARS-CoV-2 infection, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, if antiviral therapy prevents long COVID and viral sequalae in healthy young marines.
Click arrow to play
Download TWiV 1162 (29 MB .mp3, 48 min)
Subscribe (free): Apple Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
Mycoplasma pneumoniae infections increasing (CDC)
Polio vaccination campaign restarts (Reuters)
North Gaza polio campaign postponed (Reuters)
1St clade 1b mpox in UK (GOV.UK)
UK imports mpox (CIDRAP)
Clinical trial of MVA-BN for children (Bavarian-Nordic)
How to stop Marburg virus (Rwanda Biomedical Centre)
Marburg Virus fact sheet (Rwanda Biomedical Centre)
Laboratory confirmed influenza associated hospitalizations 2010-2023 (CDC)
Influenza weekly surveillance report: cliff notes (CDC FluView)
Mucosal nirsevimab levels in breakthrough bronchiolitis (LANCET Infectious Diseases)
RSV NETwork (CDC RSV)
Respiratory virus activity (CDC Respiratory Illnesses)
COVID-19 deaths (CDC)
COVID-19 national and regional trends (CDC)
Waste water scan for 11 pathogens (WastewaterSCan)
UK public health data tracker (UKHSA)
COVID-19 variant tracker (CDC)
SARS-CoV-2 genomes galore (Nextstrain)
Repeat COVID-19 mRNA vaccination contributes to mucosa immunity (Science Translational Medicine)
XBB.1.5 mRNA booster vaccination limited mucosal immunity (Science Translational Medicine)
I repeat: COVID mRNA booster vaccinations suboptimal respiratory mucosal immunity (Science Translational Medicie)
Facial Palsy after COVID-19 vaccination? (Emerging Infectious Diseases)
New preventive COVID-19 agent (ISDA)
IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (IDSA)
Where to get pemgarda (Pemgarda)
EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
Fusion center near you….if in NY (Prime Fusions)
CDC Quarantine guidelines (CDC)
NIH COVID-19 treatment guidelines (NIH)
Infectious Disease Society guidelines for treatment and management (ID Society)
Viral and symptom rebound following monoclonal antibody therapy (JID)
Drug interaction checker (University of Liverpool)
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID (Scientific Reports)
Molnupiravir safety and efficacy (JMV)
Convalescent plasma recommendation for immunocompromised (ID Society)
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo (JAMA Network Open)
What to do when sick with a respiratory virus (CDC)
When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)
Managing healthcare staffing shortages (CDC)
Steroids, dexamethasone at the right time (OFID)
Anticoagulation guidelines (hematology.org)
Clinical and functional assessment of SARS-CoV-2 sequelae among young marines
(LANCET: Regional Health Americas)
Letters read on TWiV 1162
Dr. Griffin’s COVID treatment summary (pdf)
Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
The post TWiV 1162: Clinical update with Dr. Daniel Griffin first appeared on This Week in Virology.
“Vincent: You see there are some issues with the Science paper – as we’ve discussed. I am just hoping Ian can get around those issues. Do you understand what I am saying?
Alan: Yes. As I understand it these samples are going to be coded and blinded by somebody who has not been involved with any of this XMRV story to date and that that coding system would be kept confidential presumably with robust security – because you know there are people that have been involved with this story who are now in Lipkin’s lab or closely associated with it – so this has got to be done very very carefully and hopefully that will be the case.
Vincent: Right…” Are you, Alan Dove and Prof. Racaniello, implying you think Mikovits and/or others on the Lombardi paper lied about the results or blinding? I think circumspection is a natural human reaction to the allegations of theft that have been made against Dr. Mikovits (my impression is that she was at least out of line, maybe worse, but I think we need to wait for all the evidence in those cases to come out before we make final conclusions).And this rigorous study by Lipkin won’t be believed by you, you say, if the results confirm the Lombardi paper- the burden is on them, not the other less rigorous studies.You guys do make some good points. There are multiple lines of evidence against XMRV infecting humans in vivo. However, your assumptions and conclusions about the “pro-HGRV” scientists seem to me to be biased once again as compare to your conclusions about the “anti-HGRV” scientists and your silence on the outright fraudulent ‘scientists’ involved in XMRV and in ME science in general- eg CDC, Wessely school including McClure. There is some circumstantial evidence of potential ‘sketchiness’ re Mikovits and you have no problem assuming the worst (which is a normal human reaction), but why the double standard when it comes to the “other side” – the proven frauds who wage war on ME science? I have asked this numerous times and don’t get an answer. I appreciate that you published David Tuller’s piece on CDC, but that’s all you’ve done. In this podcast you mentioned that he wrote the piece but you didn’t mention that it’s another documentation of the fake science done on ME by CDC. This seems biased to me.
If it bothers you so much that $1 bucks was used for a grant on Chronic Fatigue maybe we could just consider it “part” of the money that CDC got to study CFS and fibromyalgia and they “lost” somewhere along the way!
Sorry make that $1 million bucks.
Hi guys, great wrap-up. You brought up the idea of a shorter version of TWIV for a wider audience for radio. I wonder if it would work if after you taped a full TWIV, you did a 5 minute highlight of one of the interesting pieces you talk about in the podcast, instead of covering everything. You could start with a 5 minute explanation of the ferret flu paper and what it means for science and science publishing. Then go from there? You could model it after SkyWatch, a show from the Baltimore NPR station. (http://hubblesite.org/explore_astronomy/skywatch/#333)
Might work and then you could push it to local NPR stations too.
Matt